| Literature DB >> 32251473 |
Robert A Kozak1, Russell S Fraser2, Mia J Biondi3,4, Anna Majer5, Sarah J Medina5, Bryan D Griffin5, Darwyn Kobasa5,6, Patrick J Stapleton7, Chantel Urfano5, Giorgi Babuadze8, Kym Antonation5, Lisa Fernando5, Stephanie Booth5, Brandon N Lillie9, Gary P Kobinger5,8.
Abstract
Crimean-Congo hemorrhagic fever virus (CCHFV) is a tick-borne virus that can cause a hemorrhagic fever in humans, with a case fatality rate of up to 40%. Cases of CCHFV have been reported in Africa, Asia, and southern Europe; and recently, due to the expanding range of its vector, autochthonous cases have been reported in Spain. Although it was discovered over 70 years ago, our understanding of the pathogenesis of this virus remains limited. We used RNA-Seq in two human liver cell lines (HepG2 and Huh7) infected with CCHFV (strain IbAr10200), to examine kinetic changes in host expression and viral replication simultaneously at 1 and 3 days post infection. Through this, numerous host pathways were identified that were modulated by the virus including: antiviral response and endothelial cell leakage. Notably, the genes encoding DDX60, a cytosolic component of the RIG-I signalling pathway and OAS2 were both shown to be dysregulated. Interestingly, PTPRR was induced in Huh7 cells but not HepG2 cells. This has been associated with the TLR9 signalling cascade, and polymorphisms in TLR9 have been associated with poor outcomes in patients. Additionally, we performed whole-genome sequencing on CCHFV to assess viral diversity over time, and its relationship to the host response. As a result, we have demonstrated that through next-generation mRNA deep-sequencing it is possible to not only examine mRNA gene expression, but also to examine viral quasispecies and typing of the infecting strain. This demonstrates a proof-of-principle that CCHFV specimens can be analyzed to identify both the virus and host biomarkers that may have implications for prognosis.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32251473 PMCID: PMC7162549 DOI: 10.1371/journal.pntd.0008105
Source DB: PubMed Journal: PLoS Negl Trop Dis ISSN: 1935-2727
Number of upregulated and downregulated genes at day 1 and 3 post-infection (DPI).
| Cell Lines | 1 DPI | 3 DPI | ||
|---|---|---|---|---|
| Upregulated | Downregulated | Upregulated | Downregulated | |
| HepG2 | 12 | 0 | 34 | 3 |
| Huh7 | 10 | 3 | 177 | 104 |
Kinetic changes in pathway type at 1 and 3 days post-infection by cell line.
| Days Post-Infection | Pathway Name | Entities Found ( | |
|---|---|---|---|
| HepG2 | Huh7 | ||
| 1 | Immune System | 15 (3.4x10-6) | 10 (9.5 x10-3) |
| Interferon alpha/beta signalling | 15 (1.1x10-16) | 8 (6.7x10-10) | |
| Interferon Signalling | 15 (1.1x10-16) | 8 (6.5x10-7) | |
| Cytokine Signalling in Immune system | 15 (6.0x10-10) | 8 (2.2x10-3) | |
| Interferon gamma signalling | 4 (8.1x10-4) | ||
| Antiviral mechanism by IFN-stimulated genes | 3 (4.1x10-3) | 3 (3.2 x10-3) | |
| ISG15 antiviral mechanism | 3 (4.1x10-3) | 3 (3.2 x10-3) | |
| Negative regulators of DDX58/IFIH1 signalling | 2 (2.8 x10-2) | ||
| 3 | Immune System | 36 (2.7x10-9) | 83 (3.1x10-4) |
| Cytokine Signalling in Immune system | 33 (1.1x10-14) | 66 (2.8x10-9) | |
| Interferon Signalling | 31 (1.1x10-16) | 43 (1.8x10-15) | |
| Interferon alpha/beta signalling | 23 (2.6x10-13) | 26 (2.6x10-13) | |
| Interleukin-4 and 13 signalling | 21 (1.3x10-9) | ||
| Interferon gamma signalling | 15 (1.3x10-12) | 23 (2.1x10-9) | |
| Interleukin-10 signalling | 10 (1.5x10-4) | ||
| Platelet degranulation | 8 (1.1x10-3) | ||
| Response to elevated platelet cytosolic Ca2+ | 8 (8.8x10-3) | ||
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | 6 (2.9x10-2) | ||
| Post-translational protein phosphorylation | 6 (6.1x10-3) | ||
| Senescence-Associated Secretory Phenotype (SASP) | 5 (3.7x10-2) | ||
| Antiviral mechanism by IFN-stimulated genes | 4 (1.5x10-2) | ||
| ISG15 antiviral mechanism | 4 (1.5x10-2) | ||
| Interleukin-18 signalling | 3 (4.5x10-4) | ||
| RUNX3 regulates CDKN1A transcription | 3 (3.7x10-2) | ||
| Regulation of IFNA signalling | 2 (3.9x10-2) | ||
| RUNX3 Regulates Immune Response and Cell Migration | 2 (1.6x10-2) | ||
| TGFBR2 MSI Frameshift Mutants in Cancer | 1 (2.4x10-2) | ||
ap-value
Fig 1Dysregulation of gene expression 1 and 3 days post CCHFV infection.
Comparison of A), B) HepG2 and Huh7 C), D) uninfected (orange square and infected with CCHVF (light blue square) at A), C) 1 and B), D) 3 DPI. Scale represents fold-change from -3 (dark blue square) (3-fold downregulation) to +4 (red square) (4-fold upregulation). Data is from three biological replicates.
Fig 2Networks of interacting genes identified using STRING from the RNA-seq results from Huh7 cells at 3 DPI.
Top upregulated genes at 1 and 3 days post-infection by cell line.
| Days Post-Infection | Gene | Function | Fold-Change | |
|---|---|---|---|---|
| HepG2 | Huh7 | |||
| 1 | RIG-I signalling pathway | 9.2 | ||
| Epithelial stromal interaction 1, plasminogen regulation | 6.7 | |||
| ds-RNA antiviral response | 6.2 | |||
| Interferon alpha inducible protein, regulation of apoptosis | 4.8 | 5.1 | ||
| Interferon alpha/beta signalling | 4.8 | |||
| Regulator of Type I interferon production/Type I interferon-signalling pathway | 4.5 | 3.2 | ||
| Myxovirus (influenza virus) resistance 1, interferon-inducible protein | 4.5 | 4.0 | ||
| Type I interferon signalling pathway | 3.6 | |||
| Cellular lipid metabolic processes | 3.5 | |||
| Protein ubiquitination | 3.2 | |||
| Regulator of type I interferon production | 3.0 | |||
| Type I interferon signalling pathway | 3.2 | 2.8 | ||
| Type I interferon signalling pathway | 1.8 | |||
| 3 | Glutathione metabolic process | 39.7 | ||
| Cytokine mediated signalling | 28.8 | |||
| RIG-I signalling pathway | 11.2 | 6.8 | ||
| cytokine mediated signalling, ubiquitination | 11.0 | |||
| Type I interferon signalling pathway | 9.6 | |||
| Type I interferon signalling pathway | 8.7 | |||
| Epithelial stromal interaction 1, plasminogen regulation | 8.2 | 8.6 | ||
| Ras protein signal transduction | 7.8 | |||
| pyrimidine nucleotide metabolism | 7.5 | |||
| ds-RNA antiviral response | 7.3 | 9.4 | ||
| Interferon alpha inducible protein, regulation of apoptosis | 8.3 | |||
| Response to IL-2 signalling | 7.9 | |||
| Bone morphogenic protein signalling pathway | 7.6 | |||
| TLR signalling pathways (TLR2,5,9,10) | 7.6 | |||
| Interferon signalling pathway, apoptosis | 7.4 | |||
| Protein ubiquitination | 6.8 | |||
| CAP-GLY domain containing linker protein 2, regulator of wound healing | 6.2 | |||
Fig 3Networks of interacting genes involved in platelet degranulation and activation pathways identified using STRING from the RNA-seq results from Huh7 cells at 3 DPI.
Fig 4Reads aligned to the CCHFV genome in infected Huh7 and HepG2 cells at 1 and 3 days post-infection.